Switching From Intravenous to Subcutaneous Immunoglobulin Maintenance Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Yelda Su, Pieter A. van Doorn, Bart C. Jacobs, Krista Kuitwaard · 2026

Read Switching From Intravenous to Subcutaneous Immunoglobulin Maintenance Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy by Yelda Su, Pieter A. van Doorn, Bart C. Jacobs, Krista Kuitwaard (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13451955.txt.

Description

Yelda Su and co-authors follow nerve disease patients who swapped antibody infusions for self-injected treatment at home. Their 2026 case series concerns CIDP, a chronic immune attack on the nerves, where maintenance immunoglobulin keeps strength stable. Guidelines bless a switch from intravenous to subcutaneous dosing at the same amount, but the best conversion was unproven.

Stable patients at one Dutch medical center who made the one-to-one switch were reviewed after the fact. Decline was counted by grip and muscle strength and disability scores within four months. The series tests whether the simple equal-dose rule holds in real clinics, which matters for patients trading hospital days for home care.

Catalog record

CREATORYelda Su, Pieter A. van Doorn, Bart C. Jacobs, Krista Kuitwaard
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13451955

Browse the full library · About the Tower of Babel